News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired Pneumonia


4/15/2010 9:45:45 AM

BERNE, Switzerland--(BUSINESS WIRE)--Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), with all patients completing the treatment for hospital-acquired pneumonia (HAP) and ventilator-acquired pneumonia (VAP) caused by P. aeruginosa achieving an effective clearance of pneumonia as well as a 100% survival rate. Panobacumab, a fully human IgM monoclonal antibody, is a first-in-class immunotherapy for these life-threatening infections, and this clinical trial reveals its potential as a more effective treatment than standard antibiotic therapy alone.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES